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ALS-FUS pathology revisited: singleton FUS
mutations and an unusual case with both a
FUS and TARDBP mutation
Andrew King1,2*†, Claire Troakes2,3†, Bradley Smith3, Matthew Nolan2,3, Olimpia Curran1,2, Caroline Vance3,
Christopher E. Shaw3† and Safa Al-Sarraj1,2†
Abstract
Introduction: Mutations in the FUS gene have been shown to be a rare cause of amyotrophic lateral sclerosis (ALS-FUS)
and whilst well documented clinically and genetically there have been relatively few neuropathological studies.Recent
work suggested a possible correlation between pathological features such as frequency of basophilic inclusions in
neurons and rate of clinical decline, other studies have revealed a discrepancy between the upper motor neuron features
detected clinically and the associated pathology. The purpose of this study was to describe the pathological features
associated with more recently discovered FUS mutations and reinvestigate those with well recognised mutations in an
attempt to correlate the pathology with mutation and/or clinical phenotype. The brains and spinal cords of seven cases
of ALS-FUS were examined neuropathologically, including cases with the newly described p.K510E mutation and a case
with both a known p.P525L mutation in the FUS gene and a truncating p.Y374X mutation in the TARDBP gene.
Results: The neuropathology in all cases revealed basophilic and FUS inclusions in the cord. The density and type of
inclusions varied markedly between cases, but did not allow a clear correlation with clinical progression. Only one case
showed significant motor cortical pathology despite the upper motor neuron clinical features being evident in 4 patients.
The case with both a FUS and TARDBP mutation revealed FUS positive inclusions but no TDP-43 pathology. Instead there
were unusual p62 positive, FUS negative neuronal and glial inclusions as well as dot-like neurites.
Conclusions: The study confirms cases of ALS-FUS to be mainly a lower motor neuron disease and to have pathology
that does not appear to neatly correlate with clinical features or genetics. Furthermore, the case with both a FUS and
TARDBP mutation reveals an intriguing pathological profile which at least in part involves a very unusual staining pattern
for the ubiquitin-binding protein p62.
Introduction
The discovery of the TAR DNA binding protein 43
(TDP-43) as a component of the neuronal inclusions in
most cases of amyotrophic lateral sclerosis (ALS), and
many cases of frontotemporal lobar degeneration
(FTLD) marked a significant advance in the research
into these devastating neurodegenerative diseases [1, 2].
Two years later another RNA binding protein termed
fused in sarcoma (FUS) (also known as translated in
sarcoma or TLS) was seen to be associated with a small
number of ALS and FTLD cases, often in the young [3, 4].
Mutations in the FUS gene on chromosome 16, have been
shown to be a rare cause of amyotrophic lateral sclerosis
(ALS-FUS), being responsible for approximately 4 % of
cases of familial ALS (fALS) and fewer than 1 % of spor-
adic cases [5–7]. While there have been a number of
papers identifying the mutations associated with ALS-
FUS, actual neuropathological descriptions of such cases
are relatively sparse [8–12]. Those that have been de-
scribed do detail FUS immunopositive inclusions in the
anterior horn neurons of the spinal cord, instead of more
classical TDP-43 inclusions. So far, however, unlike the
TDP-43 proteinopathies there appears to be no obvious
clinicopathological spectrum encompassing the cases of
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ALS with FUS (ALS-FUS), and the FTLD with FUS inclu-
sions (FTLD-FUS). The two conditions seemingly have
different pathophysiologies. Whereas ALS-FUS is associ-
ated with mutations and the inclusions contain exclusively
FUS, FTLD-FUS is not usually associated with mutations
and the inclusions appear to contain a number of so-
called FET proteins including FUS but also transportin-1
[13–15]. ALS-FUS has an association with juvenile (i.e.
younger than 25 years of age) ALS especially those show-
ing abundant basophilic inclusions seen on H&E stains.
Studies have attempted to group the pathological features
of ALS-FUS into two distinct patterns, one correlating with
younger age and more rapid clinical progression, the other
with older age of onset and slower progression [8, 10].
Another publication with reference to genetic and clinical,
but not pathological analysis, has indicated that truncating
mutations in the FUS gene may give rise to a more aggres-
sive phenotype than missense mutations [16].
The purpose of the current study was to both revisit
and introduce pathological features of a series of cases of
fALS with FUS mutations, (ALS-FUS) including muta-
tions where the pathology has not to our knowledge been
reported before, and also to illustrate the unusual path-
ology of a case with both a FUS mutation and TARDBP
mutation. Attempts have also been made where possible
to correlate genetic, clinical and pathological findings to
test the assertion of there being discrete clinicopathologi-
cal subgroups.
Materials and methods
Brain and spinal cord tissue was examined from 7 cases
of ALS with previously identified FUS mutations.
Paraffin-embedded tissue blocks were obtained from the
Medical Research Council London Neurodegenerative
Diseases Brain Bank (Institute of Psychiatry, Psychology
and Neuroscience King’s College London, UK). Consent
for autopsy, neuropathological assessment and research
was obtained from all subjects.
Genetics
DNA was extracted from frozen post-mortem patient tis-
sue with standard phenol-chloroform techniques, with
one exception; which was to include a second chloroform
step to ensure clean DNA free of protein contamination.
As a point of thorough investigation, all cases were
screened for the C9ORF72 hexanucleotide GGGGCC ex-
pansion by repeat PCR as previously described [17], PCR
of all exons of SOD1 and the mutation clusters found in
exon 6 of TARDBP, and exons 6,14 and 15 of FUS. PCR
reactions for SOD1, TARDBP and FUS were confirmed by
2 % gel electrophoresis and products directly sequenced
with Big-Dye® Terminator v1.1 on an ABI3130 genetic
analyser (Applied Biosystems Pty Ltd, Warrington, UK).
Sequence chromatograms were analysed for mutations by
eye using Sequencher® 4.10 (Gene Codes Corporation,
Ann Arbor, Michigan, USA). Identified mutations were
reconfirmed by performing an independent PCR reaction
from a fresh aliquot of stock DNA.
Immunohistochemistry
Immunohistochemistry for FUS, p62 and phosphorylated
TDP-43 (pTDP-43) was performed on (where available)
the frontal lobe containing middle frontal gyrus, tem-
poral lobe with superior and middle temporal gyrus,
motor cortex (representing upper limb, lower limb, and
face regions) in all except case 2 (no face region) and 3
(no face or lower limb regions), hippocampus, amygdala,
basal ganglia, mid brain, medulla and cerebellum with
dentate nucleus and spinal cord. Tau immunohistochem-
istry was performed on the frontal and temporal cortex,
hippocampus and (where available) amygdala and immu-
nohistochemistry for α-synuclein was performed on the
medulla, pons, midbrain (and where available amygdala).
β Amyloid antibody (Aβ) was applied to frontal and tem-
poral neocortex and antibodies to CD68 were applied to
the motor cortex. Sections of cord and medulla were cut
at 14 μm thickness and stained for Luxol fast blue/Nissl.
Otherwise the blocks were cut at 7 μm thickness and
stained with haematoxylin and eosin (H&E). The rele-
vant 7 μm thick sections were also immunohistochemi-
cally stained with the mouse monoclonal antibody to p62
(1:100; BD Biosciences, Erembodegem, Belgium), phos-
phorylated tau (clone [AT-8]; 1:500; Autogen Bioclear UK
Ltd, Wiltshire, UK), α-synuclein (clone [42/α synuclein];
1:500; Novocastra Laboratories Ltd, Newcastle-upon-
Tyne, UK), CD68 (clone [PGM1]; 1:50; Dako, Glostrup,
Denmark) and Amyloid β (Aβ) (1:12,000; Chemicon,
Temecula, CA, USA), or the rabbit polyclonal antibody to
phosphorylated pTDP-43 (pS409/410-2; 1:1500); Cosmo
Bio Ltd, Tokyo, Japan), FUS (1:50; Proteintech Group,
Chicago, USA) and one case only (case 6) non-
phosphorylated (non p-)TDP-43 (1:400; Proteintech
Group, Chicago, USA, and (41-7.1) 1:200; Santa-Cruz,
Heidelberg, Germany) and additional FUS antibody
(1:200; Sigma-Aldrich, Dorset, UK) using the Leica
BONDMAX™ (Leica Biosystems, Wetzlar, Germany).
Leica BONDMAX™ epitope retrieval sets was used for
pTDP-43 and (non p-) TDP-43 (ER1 for 30 min), p62 and
FUS (ER2 for 20 min,) CD68 and tau (ER1 for 20 min).
For both α synuclein, and Aβ 80 % formic acid pre-
treatment (for 1 h) was used. Nuclei were counterstained
with Harris’ alum haematoxylin. For double labelling 7 μm
sections were cut from formalin-fixed, paraffin-embedded
blocks, dewaxed in xylene and dehydrated in 99 % indus-
trial methylated spirit. Sections were then pretreated by
microwaving in citrate buffer and blocked using normal
goat serum (1:10 for 45 min). Primary antibodies against
p62 and GFAP or p62 and FUS were then applied (p62,
King et al. Acta Neuropathologica Communications  (2015) 3:62 Page 2 of 12
BD Biosciences, Erembodegem, Belgium 1:100: GFAP,
DAKO, Glostrup, Denmark, 1:500; FUS, Sigma HPA00878,
1:100) and sections incubated at 4 °C overnight. Sections
were washed and secondary Alexa Fluor antibody (goat
anti-mouse 488 and goat anti-rabbit 568, Invitrogen,
Paisley, UK) applied for 45 min (in dark). Autofluorescence
was quenched by incubating the sections in Sudan black
for 10 min followed by numerous washes in phosphate
buffered saline before coverslip mounting using Vecta-
shield hard set media with DAPI. Sections were visualised
using a fluorescent microscope (Zeiss Axiovert S 100,
Gottingen, Germany) and images captured using ImagePro
Express (V6).
Neuropathological analysis
The densities of the respective deposited proteins (TDP-43,
p62, FUS) in neuronal/glial inclusions and neurites were
scored semi-quantitatively (absent, small numbers/low
density, moderate numbers/moderate density, large num-
bers/high density) in the areas specified above (the cervical
level of the cord was selected for this analysis). The number
of CD68 immunopositive microglial cells (absent, small
numbers, moderate numbers, large numbers) was assessed
in the motor cortex and neuronal loss in the spinal cord
sections was also scored semi-quantitatively.
Results
Genetics
Six non-synonymous and one truncation FUS mutation
were identified in seven familial ALS patients by direct
sequencing. Mutations are located in the last 30 amino
acids of the protein (residues 495–526, exons 14 and 15)
that disrupt the nuclear localisation domain of the pro-
tein (Table 1). All have been previously described and
are absent from either the NHLBI Exome Sequencing
Project (evs.gs.washington.edu/EVS/) or the Exome Ag-
gregation Consortium (exac.broadinstitute.org) [6]. All
cases were negative for C9ORF72 expansions, SOD1
mutations and the mutation hotspot of TARDBP with
one exception. Case 6 harboured both a p.P525L FUS
mutation and also a TARDBP p.Y374X truncation muta-
tion, the latter of which has been reported once previ-
ously in a French Male sporadic ALS patient with an age
of onset of 63 years [18]. DNA was unavailable from
either parent of case 6 to test for segregation of the
p.P525L and p.Y374X mutations, however, clinical
records describe the mother of case 6 to be a young
onset ALS patient in which the early onset and aggres-
sive course suggests the disease to be due to the FUS
mutation.
Clinical
The clinical features are briefly summarised in Table 1.
Cases 3, 4 and 5 have been previously described [4]. The
mean age at death was 37 (range 23–60). The duration
of time from onset of symptoms to death ranged from
7 months to more than 96 months. On reviewing the
clinical notes available all 7 patients had lower motor
neuron (LMN) symptoms some time in their disease
process. Three cases had definite bulbar symptoms (3 no
symptoms- and 1 unknown). Four cases had upper
motor neuron (UMN) symptoms, with the remaining 3
unknown. None of the cases had any history of cognitive
decline although case 4 was recorded as having learning
difficulties since childhood.
Neuropathology
The original pathological descriptions for cases 3, 4 and 5
have been previously described [4]. The neuropathological
features of all seven cases are summarised in Table 2. i)
Spinal cord: Five of the cases demonstrated severe neur-
onal loss within the anterior horn neurons of the spinal
cord (Fig. 1(a)). The other 2 cases showed moderate loss.
All of the seven cases revealed at least some basophilic
inclusions in anterior horn neurons when viewed on H&E
stains (Fig. 1(b)), however, the numbers of neurons with
these inclusions varied between frequent and sparse (this
may have been at least partially secondary to the degree of
neuronal loss). Some of the inclusions were well circum-
scribed while others resembled condensed Nissl substance
Table 1 Summarising the FUS mutations and clinical features in the 7 cases
Case Exon ΔNucleotide ΔProtein Age at death (yrs) Sex Duration (months) UMN LMN Limb/Bulbar Cog decline
1 14 c.1483C>T p.R495X 34 F 9 Yes Yes L No
2 14 c.1528A>G p.K510E 39 M 15 Yes Yes B No
3 15 c.1561C>T p.R521C 33 M 10 NA Yes NA No
4† 15 c.1561C>T p.R521C 35 F 7 Yes Yes B No†
5 15 c.1562G>A p.R521H 35 F >36 NA Yes L No
6a 15 c.1574C>T p.P525La 23 F 8 Yes Yes L No
7 15 c.1540A>G p.R514G 60 M >96 NA Yes B No
Mutations identified in the gene encoding FUS (Refseq: NM_004960). cDNA location using +1 from the ATG start site
aCase 6 also carried a previously described p.Y374X TARDBP mutation (cDNA position c.1119_1120delTT). † Learning difficulties noted in clinical records
Cog Cognitive, NA Not available, LMN Lower motor neuron signs, UMN upper motor neuron signs
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Table 2 A summary of the pathological features in the 7 cases of ALS-FUS
Case Frontal Cx Temp Cx Hippo BG Put/GP Amy Motor Mid brain Nigra Medulla XII Spinal cord Other
1 FUS -ve FUS -ve FUS -ve FUS -ve FUS -ve FUS/p62 FUS/p62: FUS: Ant horn: Moderate neuronal loss.
TDP -ve TDP -ve TDP -ve TDP -ve TDP -ve NCI + NCI + NCI + Numerous basophilic inclusions
p62 -ve p62 -ve p62 -ve p62 –ve p62-ve GCI -ve GCI + GCI ++ FUS/p62 : NCI ++, GCI +++
TDP-ve TDP-ve P62:
CD 68 + NCI + TDP -ve
GCI +
TDP-ve Lat. c-spinal tracts myelin loss: very mild
2 FUS -ve FUS -ve FUS -ve FUS/p62 FUS -ve FUS: FUS/p62: FUS/p62: Ant horn: Moderate neuronal loss. Mild FUS in cerebellar dentate
TDP -ve TDP -ve TDP -ve NCI ++ TDP -ve NCI + NCI ++ NCI ++ Moderate basophilic inclusions
p62 -ve p62 -ve p62 -ve GCI++ p62 –ve GCI + GCI ++ GCI +++ FUS: NCI ++, GCI ++
TDP-ve P62: TDP-ve TDP-ve p62: NCI +, GCI ++
NCI -ve
GCI + TDP -ve
TDP –ve
CD68 + Lat. c-spinal tracts myelin loss: mild
3 FUS -ve FUS -ve FUS -ve NA NA FUS/p62: FUS/p62: FUS: Ant horn: Severe neuronal loss.
TDP -ve TDP -ve TDP -ve -ve NCI + Moderate basophilic inclusions
p62 -ve p62 -ve p62 -ve TDP -ve NCI + GCI -ve FUS: NCI -ve, GCI +
CD68 + GCI + P62: p62: NCI +, GCI +
TDP-ve NCI -ve
GCI + TDP -ve
TDP-ve Lat. c-spinal tracts myelin loss: very mild
4 FUS -ve NA FUS -ve FUS: FUS -ve FUS: FUS -ve FUS: Ant horn: Severe neuronal loss. Mild FUS in cerebellar dentate
TDP–ve TDP -ve NCI+ TDP -ve NCI + p62: NCI -ve Moderate basophilic inclusions
p62 -ve p62 -ve GCI ++ p62 -ve GCI + NCI + GCI + FUS: NCI ++, GCI ++
p62: P62: GCI ++ P62: p62: NCI ++, GCI +++
NCI++ GCI ++ TDP-ve NCI +
GCI++ TDP-ve GCI +++ TDP -ve
TDP-ve CD68 + TDP-ve
Lat. c-spinal tracts myelin loss: very mild
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Table 2 A summary of the pathological features in the 7 cases of ALS-FUS (Continued)
Case Frontal Cx Temp Cx Hippo BG Put/GP Amy Motor Mid brain Nigra Medulla XII Spinal cord Other
5 FUS -ve FUS -ve FUS -ve FUS: FUS -ve FUS/p62: FUS: FUS: Ant horn: Severe neuronal loss.
TDP -ve TDP -ve TDP -ve NCI + TDP -ve NCI + NCI -ve NCI ++ Occasional basophilic inclusions
p62 -ve p62 -ve p62 -ve GCI+ p62 -ve GCI + GCI + GCI ++ FUS: NCI ++, GCI ++
P62-ve TDP-ve P62: P62: p62: NCI +, GCI +++
TDP-ve CD68 + NCI + NCI -ve
GCI + GCI ++ TDP -ve
TDP-ve TDP-ve
Lat. c-spinal tracts myelin loss: mild
6 FUS -ve FUS -ve FUS -ve FUS: FUS -ve FUS: FUS/p62: FUS: Ant horn: Severe neuronal loss.
TDP -ve TDP –ve TDP –ve NCI + TDP -ve NCI + NCI ++ Moderate basophilic inclusions
GCI+ P62: GCI + NCI + GCI ++ FUS: NCI ++, GCI ++
p62 : p62 : p62 : p62: NCI + P62: GCI + P62: p62: NCI +++, GCI +++
NCI +++ NCI +++ NCI + NCI+ GCI + NCI++ TDP-ve NCI ++
GCI+++ GCI+++ GCI+ GCI++ GCI++ GCI +++ TDP -ve
Neur +++ Neur ++ Neur ++ TDP-ve TDP-ve TDP-ve
CD68 +++ Lat. c-spinal tracts myelin loss: very mild
7 FUS -ve FUS -ve FUS -ve FUS: FUS -ve FUS/p62: FUS: FUS: Ant horn: Severe neuronal loss. TAU + in hippo
TDP–ve TDP -ve TDP -ve NCI ++ TDP -ve NCI + NCI -ve NCI ++ Occasional basophilic inclusions
p62 -ve p62 -ve p62 -ve GCI++ P62: GCI + GCI + GCI + FUS: NCI +, GCI ++
p62: NCI -ve TDP-ve P62: P62: p62: NCI +, GCI +
NCI -ve GCI + CD68 + NCI + NCI +
GCI + GCI –ve GCI +++ TDP -ve
TDP-ve TDP -ve TDP-ve
Lat. c-spinal tracts myelin loss: mild
Amy Amygdala, Ant anterior, BG Basal ganglia, C-spinal Corticospinal, Cx Cortex, GCI Glial cytoplasmic inclusions, GP globus pallidus, Hippo Hippocampus, Lat lateral, NA Not available, NCI Neuronal cytoplasmic
inclusions, Neur Neurites, Put Putamen, TDP TDP-43, XII XIIth nerve nucleus, -ve Not present, + small numbers/low density, ++ moderate numbers/moderate density, +++ large numbers/high density
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(Fig. 1(b) and inset). All the cases except case 3, showed
p62 positive, FUS positive neuronal cytoplasmic inclusions
(NCIs) in anterior horn cells (Fig. 1(c)-(f)) (case 3, did
show FUS positive glial cytoplasmic inclusions (GCIs) in
the cord). These FUS-positive NCIs when present, were
moderate (or moderate-frequent) in numbers apart from
case 7 where there were relatively few. Some appeared to
correspond to the basophilic inclusions. Occasional foci of
neuronophagia were evident (Fig. 2(a)). All the cases re-
vealed FUS immunopositive GCIs in the cord, but these
varied from mild to high densities. In all cases except 6,
the p62 immunohistochemistry approximately corre-
sponded to the FUS immunohistochemistry (Case 3
showed slightly more p62 positivity). Case 6 showed FUS
immunopositivity (Fig. 2(b)) and more marked p62 posi-
tivity in glial and neuronal cells. The p62 not only labelled
the type of NCIs that were immunopositive for FUS
(Fig. 2(c)), but there were some additional NCIs with more
granular and diffuse cytoplasmic staining (Fig. 2(d) and
(e)). Double labelling indeed revealed some neurons posi-
tive for both p62 and FUS, whilst others were only p62
positive (Fig. 2(e inset)). In all cases the LFB/N stain
showed minimal-very mild loss of myelin over the lateral
corticospinal tracts (Fig. 2(f)). ii) Medulla: All except case
4 showed FUS positive NCIs in the twelfth nerve nucleus
(this case had FUS positive GCIs in this region). iii) Motor
cortex: Betz cells were seen in all sections. Apart from case
6, the motor cortex revealed mild changes with little evi-
dence of neuronal loss or microglial proliferation (as
judged by CD68 immunohistochemistry). All cases except
case 3 showed FUS positive NCIs in this region. Case 6
showed marked microglial proliferation in the motor
cortex (Fig. 3(a)), and whilst there were only occasional
FUS-positive NCIs and GCIs present in the motor cortex
(confirmed by 2 FUS antibodies) the p62 revealed much
more extensive immunopositivity. This was in the form of
Fig. 1 a Reveals marked neuronal loss in the anterior horn of the spinal cord with occasional surviving angulated neurons (arrows) in case 5 (p.R521H).
H&E. b Well circumscribed basophilic inclusion (arrow) in an anterior horn neuron in case 6 (p.P525L and p.Y374X TARDBP mutation). This contrasts
with an anterior horn neuron containing some basophilic aggregate-like inclusions (inset-case 2 (p.K510E)) which resemble condensed Nissl substance
H&E. c Immunostaining for p62 illustrates neuronal (N) and glial cytoplasmic inclusions (G) in the anterior horns of the spinal cord. Case 1 (p.R495X).
Anti p62. d-f. Reveal the differing shapes and conformations of FUS-positive neuronal cytoplasmic inclusions in the anterior horns of the spinal cords
in case 1 (d-p.R495X), case 2 (e-p.K510E), and case 4 (f-p.R521C). Anti-FUS. Scale Bar (a)-140 μm, (b) (c) (e) and (b) inset-35 μm, (d) (f)-25 μm
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intense granular cytoplasmic staining in neurons and dots
in the adjacent neuropil which may have reflected affected
axons or dendrites (Fig. 3(b)). Glial cells also showed posi-
tivity, although double labelling only showed occasional
GFAP positive astrocytes co-expressing p62. iv) Other brain
regions: Of the six cases where basal ganglia were sampled
all except case 1, showed some FUS positive NCIs or GCIs.
All cases except 4, 5, and 7 revealed FUS positive NCIs in
the substantia nigra. No case showed FUS immunopositiv-
ity in the hippocampus, amygdala, frontal neocortex or
temporal neocortex. No laminar cortical necrosis was seen.
Only cases 2 and 4 showed FUS positivity (neuronal or
glial) in the dentate nucleus of the cerebellum.
v) Unusual p62 staining pattern: Case 6 showed p62
positivity in the hippocampus (but not the dentate
gyrus), mainly in the form of neurites with only small
numbers of NCIs (Fig. 3(c)), there was also mild p62
positivity in the amygdala and basal ganglia (Fig. 3(d)-(e)).
The p62 immunopositivity in the frontal and temporal
neocortex was similar in appearance to that in the motor
cortex with ramifying and granular NCIs (some with add-
itional nuclear/perinuclear staining), GCIs and dot-like
neuropil positivity (Fig. 3(f) and (g)). vi) Other proteins:
There was minimal tau staining in case 7 in the hippo-
campus, entorhinal cortex and amygdala. No other case
showed any staining for tau. The staining for Aβ, α-
synuclein and pTDP-43 was completely negative in all
cases, including case 6. In addition, case 6 revealed a nor-
mal staining pattern for non-phosphorylated TDP-43
(using 2 antibodies) despite having a TARDBP mutation.
Fig. 2 a Revealing a focus of neuronophagia in the anterior horn of the spinal cord in case 2 (p.K510E) with remnants of FUS immunopositivity. Anti-FUS.
b-e Case 6 (p.P525L and p.Y374X TARDBP mutation) also does exhibit FUS-immunopositive neuronal cytoplasmic inclusions (b) in the anterior horns of the
cord. These inclusions (c) are also immunopositive for p62. The p62 reveals additional neuronal positivity that does not appear to correspond to the FUS
immunopositivity including more granular (d) and diffuse cytoplasmic staining (e). Double labelling for FUS (red) and p62 (green) in (e) inset shows co-
localisation (yellow) in some neurons (arrowhead) but some p62 is not associated with FUS (arrow). Anti-FUS in (b). Anti-p62 in (c), (d) and (e). Anti-FUS and
anti-p62 in (e) inset. f The cord in case 1 (p.R495X) revealing very mild loss of myelin in the lateral corticospinal tracts (arrows). LFB/N. Scale Bar (a)-(c) and
(e)-30 μm, (e) inset-100 μm. (d)-40 μm, (f)-3000 μm
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Specifically there was no loss of normal nuclear staining
or cytoplasmic inclusions identified.
Discussion
Fused in sarcoma (FUS) mutations on chromosome 16
have in recent years been recognised as a relatively rare,
yet important cause of amyotrophic lateral sclerosis
(ALS). In all, such mutations represent approximately 4 %
of familial ALS cases (fALS) and less than 1 % of sporadic
cases. The FUS protein is thought to have, amongst other
functions, RNA binding properties similar to TDP-43,
which itself is associated with the majority of ALS cases
(both sporadic and familial) [19]. When investigated
neuropathologically cases of ALS-FUS have been shown
to exhibit FUS immunopositive inclusions in the anterior
horn neurons of the spinal cord, the twelfth cranial nerve
nucleus of the medulla, and/or within the neurons of the
motor cortex [8–12]. The distribution and shape of the
neuronal cytoplasmic inclusions (NCIs) have some simi-
larities to those seen in ALS associated with deposition of
TDP-43 (ALS-TDP). These NCIs can be filamentous-like
and more globular, sometimes they are also associated with
glial cytoplasmic inclusions (GCIs) and/or neurites. ALS
associated with TDP-43 positive inclusions (ALS-TDP) and
frontotemporal lobar degeneration with TDP-43 positive
inclusions (FTLD-TDP) (a pathological process associated
with frontotemporal dementia, semantic dementia and/or
progressive non fluent aphasia) are believed to represent a
clinicopathological spectrum, where some patients have
clinical and pathological features of a frontotemporal
dementia and ALS (FTLD-MND/ALS). ALS-FUS, how-
ever, appears to be distinct both clinically and
Fig. 3 Case 6 (p.P525L and p.Y374X TARDBP mutation) (a) and inset illustrates marked microglial activity in the mid-deeper laminae (between arrows) of
the motor cortex. Anti-CD68. b Showing the unusual neuronal staining for p62 in the motor cortex including processes (arrows). c-e revealing the sparse
but unusual neuronal p62 immunopositivity in the hippocampal region (c) and (c) inset including occasional NCIs (arrow), and (d) the putamen revealing
occasional NCIs (arrow). e Reveals one of the few p62 immunopositive neurons in the putamen, this is also apparently labelling the corresponding
axon/dendrites (arrows) and appears different in pattern to the occasional FUS positive NCIs. P62 immunopositivity in the frontal neocortex (f) revealing
dot-like positivity and neuronal inclusions (arrows and inset). g p62 immunopositive neuron in the temporal neocortex. These inclusions are negative
for FUS and TDP-43 and appear to label the nuclear/ perinuclear region and processes (arrows) the latter indicating likely axonal/dendritic positivity.
Anti-p62. Scale Bar (a)-300 μm, a-inset 100 μm (b)-50 μm, (c)-150 μm, (c) inset-80 μm, (d) 200 μm, (e)-50 μm, (f)-200 μm, (f) inset-80 μm, (g)-30 μm
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pathologically from the frontotemporal lobar degeneration
with FUS positive inclusions (FTLD-FUS) [13-15, 20].
Many cases of ALS-TDP, even when not associated with
cognitive decline, still show TDP-43 immunopositive inclu-
sions in the limbic regions such as hippocampus, amygdala
or entorhinal cortex. Our study confirmed previous reports
in that, apart from some inclusions in the basal ganglia and
cerebellum, there were no cases with extramotor FUS posi-
tive inclusions, further confirming the distinction between
ALS-FUS and FTLD-FUS. Indeed FTLD-FUS is not
usually associated with mutations. Instead FTLD-FUS, un-
like ALS-FUS, appears to exhibit inclusions that contain a
number of so-called FET proteins including FUS, Ewing’s
sarcoma protein (EWS) and TATA-binding protein associ-
ated factor 15 (TAF15) as well as Transportin 1 implying
abnormalities in nuclear-cytoplasmic transport [13, 15, 21].
Additionally, in ALS-FUS mutations the arginine methyla-
tion status of FUS appears to differ from that in FTLD-
FUS [14, 20, 22, 23]. Indeed the ALS-FUS mutations may
instead result in the production of a more rigid protein
which in turn appears to affect its RNA binding properties
[19, 24].
Combined with previous work, this study suggests that
in the early stages of ALS-FUS most FUS mutations pref-
erentially exert their effects on the spinal motor neurons
[11]. Whilst there have been studies attempting to correl-
ate particular FUS mutations with clinical progression,
there have been relatively few descriptions of pathology in
ALS-FUS. Waibel et al. found that cases of ALS-FUS with
truncating mutations were associated with a more aggres-
sive phenotype than missense mutations [16]. This cannot
be confirmed or refuted in this series because only one
truncating mutation case is present, however, even 2 of
the missense mutations had rapid disease progressions of
10 months or less. One pathological feature of particular
interest is that all cases showed only mild to very mild loss
of myelin in the lateral corticospinal tracts. This was in
contrast to 4 of the cases demonstrating at least some
UMN features clinically and one case (case 6) showing
evidence of marked microglial activity in the motor cortex.
Previous studies have also demonstrated this discrepancy;
the clinical presentation in ALS-FUS is often of early
proximal limb weakness sometimes with pelvic or scapu-
lar weakness, mild or late-onset bulbar features and no
significant cognitive impairment and mild or no extrapyr-
amidal abnormalities [10, 25]. Despite this, in Mackenzie
et al.’s series the paucity of UMN features did not appear
to correlate with the relatively severe FUS pathology in
the motor cortex. Similarly Baumer et al. illustrated 2
cases with the p.P525L mutation, one of whom had no
UMN features clinically yet marked degeneration of the
corticospinal tracts [8]. This was further illustrated in a
study by Riku et al. who attempted to distinguish the clini-
copathological features of the lower motor syndrome of
progressive muscular atrophy (PMA) with typical clinical
ALS [26]. They found (albeit with relatively small num-
bers) that whilst cases of ALS-FUS accounted for 15 % of
the PMA cases, all of the typical clinical ALS cases
showed TDP-43 pathology. Nevertheless, in these 15 %
(which were represented by 2 cases) there were still FUS
positive inclusions seen in the motor cortex. In their series
of 6 cases (4 with FALS) Hewitt et al. described minimal
FUS pathology in the motor cortex [9]. However, there
have been reported exceptions with one patient suffering
from a locked-in state associated with a p.K510M muta-
tion and abundant FUS pathology in the UMNs [27].
Tateishi et al. described a multiple system degeneration as-
sociated again with marked UMN pathology but this time
in patients with a p.R521C mutation which is identical to
our cases 3 and 4 and thus illustrates the degree of pheno-
typical variability [28]. Mouse models with FUS mutations
tend to support the hypothesis that it is the LMNs which
are particularly vulnerable to the structural changes that
these mutations cause [29]. All of our cases exhibited
some basophilic inclusions in the anterior horn neurons
of the cord. Mackenzie et al. attempted to define specific
groups of ALS-FUS by pathological patterns including the
density of basophilic inclusions [10]. Those with numer-
ous basophilic inclusions (including 2 cases with p.P525L
mutations) tended to have a more rapid disease progres-
sion and appeared to have fewer GCIs, compared to cases
with fewer basophilic inclusions and more glial inclusions
who had a later onset, and slower progression (including 2
cases with p.R521C mutations). Our findings do not fit
neatly into this distinct grouping. Whereas case 5 with a
p.R521H mutation would certainly appear to partially con-
form to the above criteria with a disease progression of at
least 36 months, and associated with few basophilic inclu-
sions in the cord, there were, however, moderate numbers
of GCIs. Similarly case 7 had few basophilic inclusions in
the cord, and also a relatively slow progression but again
moderate numbers of GCIs. An explanation for this
discrepancy might be due to a much younger-aged cohort
in Mackenzie et al.’s group, or alternatively in our group
the reduced numbers of basophilic neurons may just have
been a reflection of the severe neuronal loss present in the
cord. Case 6 (with a p.P525L mutation) also had moderate-
large numbers of glial inclusions, yet also had moderate
numbers of basophilic inclusions but a rapid disease
progression. However, there is an additional element in
case 6 which may have affected this, in that this patient as
well as having a p.P525L mutation also had a truncating
p.Y374X TARDBP mutation on chromosome 1. The path-
ology in this case 6 was very unusual. Whilst there was
moderate FUS pathology in the form of NCIs and GCIs in
the spinal cord, the twelfth nerve nucleus, and mild path-
ology for FUS in the motor cortex, there was marked
CD68 positivity in the motor cortex indicating increased
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microglial activity and associated with neuronal loss in this
region. There was no TDP-43 pathology seen, but there
was extensive p62 pathology, in the form of granular and
synaptic-like positivity in the cytoplasm and cell membrane
of neurons and glial cells together with extensive dot-like
and neurite-like neuropil positivity. Furthermore, this was
not only seen in the cord but also even more extensively in
the motor cortex and neocortex where there was a more
ramifying pattern to the staining in the neurons . This FUS
mutation has been described previously but not with this
associated p62 pathology [8, 10]. Daoud et al. have
described the genetics of the p.Y374X TARDBP mutation
and have predicted this to be a damaging variant, but as far
as is known there have been no pathological descriptions
[18]. P62 also known as sequestosome 1 is a ubiquitin-
binding protein, important in protein degradation via the
ubiquitin-proteasome system. As such it often can be dem-
onstrated in association with, and sometimes co-localised
with, abnormal proteins in specific neurodegenerative
diseases such as tangles in Alzheimer’s disease and Lewy
bodies in Parkinson’s disease. It is also seen in association
with TDP-43 in FTLD-TDP and ALS associated with
TDP-43. It is intriguing that despite the TARDBP muta-
tion in case 6 there was no TDP-43 pathology. Whereas
this patient died at the age of 23, the only known reported
patient with the same TARDBP mutation died at the age
of 63 so it may simply be that the FUS mutation is the
more “aggressive” mutation and they act independently
such that we are seeing the end stage of the FUS-ALS dis-
ease and the earliest (if any) stage of the ALS-TDP disease
[18]. This, however, does not adequately explain the
unusual p62 expression. Daoud et al. predicted that the
actual TARDBP mutation produces a truncated TDP-43
protein due to a premature stop codon removing the last
41 amino acids [18]. It would therefore be logical that any
inclusions could not be detected with the relatively
specific antibody to pTDP-43. What is more difficult to
explain is that the antibodies to the wild type (non-phos-
phorylated) TDP-43 also showed no inclusions and indeed
no loss of normal nuclear TDP-43 immunopositivity.
Homma et al. have described a missense TARDBP muta-
tion with minimal TDP-43 pathology [30], and it may be
that the TDP-43 pathology in our case is also so subtle it
has been missed. It is also possible that the mutation
resulted in unusual species of TDP-43 not detectable by
conventional antibodies. Although not directly compar-
able with a truncating mutation it is interesting that
mouse models that have undergone conditional gene
depletion of TARDBP in the spinal cord neurons do not
show TDP-43 positive inclusions (unlike missense muta-
tion models) but do show an unusual pattern of polyubi-
quitinated proteins in the neurons but not in the form of
the usual inclusions [31–33]. Therefore in this case the
p62 expression may be showing 2 distinct patterns, one
simply shadowing the FUS pathology and one correspond-
ing to an unusual pattern of polyubiquitinated proteins
similar to the TARDBP depletion model described. Whilst
the p62 pathology may indicate damage or dysfunction in
individual neurons or glial cells the relationship cannot be
that straightforward since the intensity of such p62 immu-
nopositivity in the neocortex does not appear to correlate
with cognitive decline. In this regard it can perhaps be
compared to the extensive p62 and ubiquitin immunopo-
sitivity seen in the cerebellum in cases of FTLD or ALS
with the C9ORF72 repeat expansion. The immunoexpres-
sion here again does not appear to be related to neuronal
loss or cerebellar signs, however, there is still a debate as
to whether there is a toxic effect of the offending ubiquiti-
nated dipeptide repeat proteins [34–36]. There also re-
mains the theoretical possibility that there is a third
mutation present (in the p62/sequestosome 1 (SQSTM1)
gene) in this case which has given rise to the p62 path-
ology [37].
As far as is known this is the first pathological
description of a patient with ALS-FUS associated with a
p.K510E mutation. Syriani et al. described the clinical and
genetic features of 2 cases with this mutation, one was
32 years old at death the other 43, and both had a rapid
clinical course (8 and 10 months respectively), and neither
demonstrated UMN signs [38]. Our case (case 2) did dem-
onstrate some UMN and bulbar signs and a moderately
rapid disease progression of 15 months. Pathologically
what was interesting was the moderate to severe FUS in-
volvement of the cord and medulla but again not the
motor cortex. Also there were moderately numerous FUS
positive NCIs and GCIs in the midbrain and basal ganglia.
The p.R514G missense mutation again has been detected
previously and has been predicted to have a relatively mild
phenotype [16], which is in keeping with our case 7,
again to our knowledge the pathology associated with this
mutation has not been reported. There were few basophilic
inclusions and moderate numbers of FUS positive GCIs.
Conclusions
In conclusion, our study has revealed the neuropatho-
logical features associated with both some well-known
and more recently discovered FUS mutations. It has sup-
ported previous studies which have demonstrated that
ALS-FUS is predominantly a lower motor neuron dis-
ease, it has also indicated that there can be marked clin-
ical and pathological variability even between patients
with identical mutations. Accordingly, at least in our co-
hort, the relationship between the density of basophilic
inclusions in neurons, density of GCIs and clinical
course in ALS-FUS is not straightforward. Furthermore,
the study characterises the pathology of a patient with
both a FUS and TARDBP mutation. The possible inter-
action of 2 pathological processes is intriguing but
King et al. Acta Neuropathologica Communications  (2015) 3:62 Page 10 of 12
before it can be understood more neuropathological data
will be required on cases with the rare unusual truncat-
ing TARDBP mutation, and any other rare combinations
of TARDBP and FUS mutations. Alternatively a mouse
model incorporating both would provide some answers
regarding the relative contributions of the two mutations
to the disease pathogenesis and the normal intracellular
roles and interactions of both TDP-43 and FUS.
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